Anti-Human EGFR Recombinant Antibody (Futuximab) (CAT#: TAB-H35)

Recombinant Chimeric (human/mouse) antibody to Human EGFR. Futuximab (INN) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and also binds to HER1.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
IF

Figure 1 Antibodies Internalizes and Degrades EGFRvIII.

Figure 1 Antibodies Internalizes and Degrades EGFRvIII.

Quantification of EGFRvIII detected in spots after antibody treatment for the indicated periods.

Keir, S. T., Chandramohan, V., Hemphill, C. D., Grandal, M. M., Melander, M. C., Pedersen, M. W., ... & Bigner, D. D. (2018). Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. Journal of neuro-oncology, 138(3), 489-498.

WB

Figure 2 Antibodies Internalizes and Degrades EGFRvIII.

Figure 2 Antibodies Internalizes and Degrades EGFRvIII.

The cell line NR6M was treated with negative control mAb (Neg Ctrl mAb), futuximab, modotuximab, or Sym004 for 24 or 48 h, followed by harvest of cell lysates and detection of EGFRvIII by Western blot.

Inhib

Figure 3 Effect of Sym004, and Its Components Futuximab and Modotuximab, in Subcutaneous Glioblastoma Xenograft Tumor Models.

Figure 3 Effect of Sym004, and Its Components Futuximab and Modotuximab, in Subcutaneous Glioblastoma Xenograft Tumor Models.

EGFRwt (D08-0308MG) patient-derived GBM xenografts passaged in athymic mice were injected s.c. in the right flank of Balb/c nu/nu mice. Sym004, futuximab, and modotuximab were administered at a dose of 50 mg/kg i.p. twice weekly for 5 weeks (10 treatments in total).

Keir, S. T., Chandramohan, V., Hemphill, C. D., Grandal, M. M., Melander, M. C., Pedersen, M. W., ... & Bigner, D. D. (2018). Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.ournal of neuro-oncology, 138(3), 489-498.

Inhib

Figure 4 Sym004 shows potent inhibition in Subcutaneous Glioblastoma Xenograft Tumor Models.

Figure 4 Sym004 shows potent inhibition in Subcutaneous Glioblastoma Xenograft Tumor Models.

EGFRwt (D08-0308MG) patient-derived GBM xenografts passaged in athymic mice were injected s.c. in the right flank of Balb/c nu/nu mice. Sym004, futuximab, and modotuximab were administered at a dose of 50 mg/kg i.p. twice weekly for 5 weeks (10 treatments in total).

Keir, S. T., Chandramohan, V., Hemphill, C. D., Grandal, M. M., Melander, M. C., Pedersen, M. W., ... & Bigner, D. D. (2018). Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.rnal of neuro-oncology, 138(3), 489-498.


Specifications

  • Host Species
  • Mouse
  • Derivation
  • Chimeric (human/mouse)
  • Type
  • IgG1 - kappa
  • Specificity
  • EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens]
  • Species Reactivity
  • Human
  • Applications
  • IF, WB, Inhib
  • CAS
  • 1310460-85-5
  • Generic Name
  • futuximab
  • Related Disease
  • Colorectal cancers

Product Property

  • Purity
  • Purity >95% by SDS-PAGE.

Applications

  • Application Notes
  • The Human EGFR antibody has been reported in applications of Immunofluorescence, Western Blot, Inhibition.
    Inhib: 50 mg/kg.

Target

  • Alternative Names
  • futuximab;1310460-85-5;992 DS;Sym004;EGFR;epidermal growth factor receptor;epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) , ERBB;ERBB1;erythroblastic leukemia viral (v erb b) oncogene homolog (avian);prot

Related Resources

  • Related Diseases
  • Related Signaling Pathways

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Futuximab"

Afuco™ Anti-EGFR ADCC Recombinant Antibody (Futuximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Chimeric (human/mouse) antibody to Human EGFR. Futuximab (INN) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and also binds to HER1.

See other products for "EGFR"

Fc Glycosylation

High-mannose Glycoform

CAT Product Name Application Type
Gly-055LC-1 Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) ELISA Chimeric antibody (mouse/human)

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-167LC Recombinant Anti-Human EGFR Antibody (Non-glycosylated) ELISA Human antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0183MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody
BRD-0668MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody

Neutralizing Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-165 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Matuzumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-464CQ Afuco™ Anti-EGFR ADCC Recombinant Antibody (Tomuzotuximab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-003 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Cetuximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-040 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Zalutumumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody
AFC-TAB-119 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Necitumumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-H35. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare